Podcasts about tigerlily foundation

Maimah Karmo shares her story with triple-negative breast cancer and how she founded the Tiger Lily Foundation. Maimah emphasizes the importance of self-advocacy, community support, and education in traversing healthcare challenges. She shares her experience of being dismissed by doctors due to her age and ethnicity, and how this motivated her to create an organization that empowers women of color facing similar struggles. Key Highlights: 1. Trust your gut, it could save your life. 2. Don't do it alone, community is what will help you do what you need to do even if you're afraid. 3. Be the best advocate you can be for yourself, this is your life and your body – you are worth  the fight. About our guest: Maimah Karmo is the Founder/CEO of the Tigerlily Foundation (Tigerlily) and an eighteen-year survivor of breast cancer. On February 28, 2006, at 4:45 p.m., Maimah was diagnosed with Stage 2 triple negative breast cancer. She had no family history and was 32-years old.  While undergoing her second round of chemotherapy, she made a promise to God that if she survived, she would create an organization to educate, empower, advocate for and support young women affected by breast cancer.  A first-generation immigrant from Liberia, who has experienced disparities first-hand, she is a leader in the women's health field, creating and implementing national health initiatives for women and girls, with a goal of eliminating disparities of age, stage and color.  Under Maimah' s leadership, Tigerlily Foundation has launched national and global health initiatives focused on ending disparities, through the #InclusionPledge, partnering with global stakeholders, with a call to action to recognize health disparities as a social justice issue; and working to end disparities for black women in our lifetime. She is a global thought leader, health advocate and philanthropist, committed to justice and equity for all. Maimah also works directly with women and their families to connect the patient with better care and knowledge. through events such as the Annual Young Women's Breast Health Day on the Hill and other philanthropic efforts and successful educational and support programs.  You can find Maimah on Twitter, on Instagram, and on Facebook.  Check out the Tigerlily Foundation here. Key Moments: At 6 minutes 25 seconds “I ended up finding the flower one day, the tiger lily… It's like a woman, beautiful, different layers to her, and also when people are going through treatment there's a sense of so much fear. You do lose things in a way. You may lose your petals: your hair, eyebrows, eyelashes, breasts, other parts of your body, male or female. The flower is a perennial, so in the fall, winter, the petals fall off but in the spring and summer, they blossom again.  I want people who are coming to Tigerlily to feel that sense of: I'm going through this time of dormancy and things are falling off, but that means I could grow and transform into something beautiful and amazing and just badass.You could find beauty, strength and be transformed throughout the cancer journey.” Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only.  This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

In this series finale, we meet Maimah Karmo, President and CEO of the Tigerlily Foundation, and learn about her journey to end disparities for young breast cancer patients of color. If you like this series, be sure to subscribe, leave a rating a review, share on social media, and please tell your community to check it out.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join A Cure in Sight, an ocular melanoma foundation, to interview Debora Barton at TScan Therapeutics. Tune in for an episode full of hopeful advances in treatment avenues and research. Check out their website, www.tscan.com for information on their sites open for prescreening as well as their treatment protocol. You can learn more about the uveal melanoma specific trials at the links below: NCT05812027 (screening protocol) and NCT05973487 (treatment protocol). Debora Barton, M.D., is the Chief Medical Officer at TScan Therapeutics. Debora, a clinical oncologist experienced in developing cell therapies, brings to TScan nearly two decades of expertise across global clinical research and development. Prior to joining TScan, Debora was the Chief Medical Officer at Carisma Therapeutics Inc., where she was responsible for the clinical development of a First-in-Human, First-in-Class cell therapy, including clinical operations, medical affairs, and safety. Previously, Debora was the Senior Vice President, Head of Clinical, Head of Safety at Iovance Biotherapeutics, Inc., where she built a team to run several Phase 2 studies in solid tumors and led clinical efforts related to regulatory interactions. Prior to Iovance, she held positions of increasing responsibility at biotech and pharmaceutical companies including Advanced Accelerator Applications S.A., Celgene Corporation, and Novartis. Debora is a board-certified clinical oncologist (M.D.), and a board member for the American Cancer Society, the Tigerlily Foundation (medical advisory board), and Arovella Therapeutics Ltd (non-executive director). She holds an M.D. from Pontificia Universidade Catolica Sao Paulo and completed her fellowship in Oncology at Federal University of Sao Paulo in Brazil.   Read a summarized transcript of this episode at the link.    ANNOUNCEMENTS: Steps for Sight 2024 is underway! Join the steps movement or donate to research January only at www.charityfootprints.com/SFS2024 5K SITES ARE OPEN FOR REGISTRATION NEAR YOU! Start your team and bring your community to get involved! Highest record for registrations is 306! Who can top it!? Fundraisers have a record of $30K+ in Palo Alto–who can help beat that!?  January 20, 2024 Orlando FL https://runsignup.com/Race/FL/Orlando/LookinForACureTampa January 21, 2024, Miami FL https://runsignup.com/Race/FL/Miami/LookinForACureMiami March 24, 2024, Tampa, FL https://runsignup.com/Race/FL/Tampa/LookinForACureTampaFL March 30, 2024, Brooklyn, NY https://runsignup.com/Race/NY/Brooklyn/LookinForACureBrooklyn May 18, 2024, Raleigh, NC https://runsignup.com/Race/NC/Raleigh/LookinForACureRaleigh Head to our site to register for a 5K Lookin' for a Cure near you for the remainder of the year!! www.lookinforacure.org  COMING OCTOBER 2024: Eye Believe Survivorship Seminar in Scottsdale, Arizona - Join A Cure in Sight and Dr. Justin Moser from Honorhealth Research Institute for our upcoming survivorship seminar in the sunny state of Arizona! Details on registration coming soon! Subscribe to the newsletter to stay in the know Newsletter link Email contact@acureinsight.org for questions regarding any upcoming events! ********* Be sure to follow us on Facebook, Twitter, Linked In, or  Instagram @acureinsight, for more stories, tips, research news, and ideas to help you navigate this journey with OM! *A Cure in Sight is a 501c3 organization. All donations made can help fund our podcast to educate patients, fund research, aid patients, and more! Donate $10 $15 $20 today to help A Cure in Sight in their quest to find a cure. Contribute via  PAYPAL OR VENMO or reach out directly to contact@acureinsight.org 

Being Latina isn't a one-size fits all category - here at FTBOU we have voices that represent Columbia, Mexico, and Puerto Rico, to name a few. On this episode, you'll hear how some of the Latina's in our community viewed their culture as it affected (or didn't affect) them navigating breast cancer treatment. HOSTS Miranda Gonzales At age 39, Miranda found a lump in her breast and was told it was nothing, which lead to a new lump 6 months later and a diagnosis of Stage 3 hormone positive IDC. What followed was a year that included chemotherapy, a double mastectomy with immediate DIEP flap reconstruction, and radiation.  Being a young Hispanic woman, she often felt out of place among the mostly older non-Hispanic patients. Most support groups she encountered were populated with women who were mostly affluent, had retired or had adult children. A year after finishing active treatment, she began to volunteer at Houston Methodist Hospital on the infusion floor as a CanCare.org volunteer, visiting with patients while they go through chemotherapy infusions.  She also began to lead the HMH local support group, in conjunction with Reconstruction of a Survivor. She is a volunteer turned employee with Wig Out.org, which offers free wig kits to uninsured and underinsured women, out of Smith Clinic and LBJ Hospital, part of Harris Health Systems in Harris County. These three activities allowed her to meet women at the beginning of their diagnosis, helping her to seek out young Hispanic women that needed the support she did not have. She has attended Project Lead, is e a YSC RISE Advocate, as well as an Ambassador with For the Breast of Us, an online community dedicated to supporting women of color diagnosed with breast cancer. She now sits on their Community Partnership Board. Lastly, she's recently accepted a position with SHARE Cancer Support, working with the “Our MBC Life” podcast, which is dedicated to amplifying the voices and sharing the realities of those living with metastatic breast cancer.  You can find her on IG @MirLorDehGon GUESTS Araceli Cortez My name is Araceli Cortes and I am 36 years old. My husband and I recently celebrated our tenth year anniversary and we have one child, Leonardo, who is 3 years old. My husband and I own a small business under the name of Tejas Insurance Agency and specialize in providing our customers with different types of insurance policies. In the middle of a pandemic in 2020, I felt a bump on my left breast and decided to schedule a second mammogram that same year. After more testing, I was told that I had breast cancer. I was given my diagnosis: Invasive ductal carcinoma, high nuclear grade 3, Her2+. Not knowing what my journey would look like ahead, I decided to focus on gathering information and researching more about the type of cancer I had. The more I learned and researched, the more confident I felt with my decisions along the way. I have completed my chemotherapy, had nipple-sparing mastectomy surgery, 30 rounds of radiation sessions, 14 cycles of targeted therapy, and am currently on Endocrine Therapy (hormonal therapy) waiting for my Reconstruction surgery in mid July 2022. I thank God for my family and friends, cancer support groups, and team of doctors every day as they all continue to support and cheer me on. This feels like it is far from over, but I take it one day at a time and just focus on making happy memories with those I love as tomorrow is never promised. You can find her at @chely048 Deb Ontiveros Deb Ontiveros is originally from Los Angeles but resides in Southern Utah. She is a Spanish/English Interpreter & Translator. Deb was diagnosed with metastatic breast cancer in April 2018. She spends her extra time advocating for breast cancer and mental health issues.  You can find her on IG, FB & Twitter: @deb4peace247    Vanessa Chapoy Vanessa ‘Baby Baddie' Chapoy was diagnosed with Stage 2A Grade 3 Invasive Ductal Carcinoma at the age of 24. She is a LatinX baddie who is passionate about early detection and is an advocate for young women of color. She is currently going through advocacy training with The Tigerlily Foundation as well as Latinas Contra Cancer. Vanessa is excited to apply what she learns into action.   Natascha Vega Natascha Vega is a Group Business Director at an advertising agency in NYC. She loves the creativity that comes with what she does and the opportunity to impact different markets and consumer needs around the globe.  Natascha is the proud “fur mom” of an amazing 17-year-old pup who has been her right hand and best companion a gal could ask for.  When she isn't deep into her work, you can find her running the streets of Manhattan, logging some miles as she loves to stay active.   On September 11, 2020, in the midst of an already chaotic year, Natascha got a call that changed her life forever after detecting a lump the month prior on her right breast: "Ms. Vega, you have  triple positive stage 2 breast cancer." Natascha underwent 5 months of chemotherapy, a failed attempt at the cold cap treatment to preserve her hair, 15 rounds of radiation and a lumpectomy surgery.  She just finished immunotherapy and is currently taking the proper medications to prevent this from happening again.   IG:  @gitana0930  www.nomelimites.net Make sure to follow us on social media: IG: forthebreastofus Twitter: thebreastofus Facebook: For the Breast of Us Private Facebook Group: Breast Cancer Baddies Breastofus.com  Baddie Behavior and Baddie 2 Baddie original theme music, podcast production, and mixing by Sincere529 (www.sincere529.com)

Maimah Karmo is the founder and CEO of The Tigerlily Foundation and a fifteen-year survivor of breast cancer. She's appeared in major media including USA Today, US News, Cosmopolitan, CBS, The Oprah Winfrey Show, and so much more. She's a sought-after speaker by the media and for policy events and a prominent philanthropist. Under her leadership, the Tigerlily Foundation has launched national and global health initiatives focused on ending disparities through the #inclusion pledge, participating with global stakeholders with a call to action to recognize health disparities as a social justice issue, and working to end disparities for Black women in our lifetime. She's a global health advocate dedicated to justice and equity for all. Maimah was born and raised in Liberia, West Africa until she was fifteen years old, and in that time she experienced three wars. Each time they escaped, and many times they returned—in large part because Maimah's parents believed in philanthropy and helping those who did not have the privilege to escape themselves. After escaping to America and starting a new life, Maimah worked to build up her own dream life. Just as it felt like it was starting to come to fruition, she found a lump in her breast. After fighting to get it examined—all of the doctors said she was too young to have breast cancer—she was finally diagnosed and treated for cancer. Women, people of color, and especially the intersection of those two are at a higher risk of being overlooked by the medical community. Most women are not taught to fight and to advocate for themselves the way Maimah was. That's why she feels responsible for advocating for those who cannot do so themselves.   The Biggest Helping: Today's Most Important Takeaway “I live by a lot of quotes, and there's a quote by Dan Millman, it says ‘Love is a warrior's sword, everywhere it cuts, it gives life, not death.' And that's something that I think, if you're here, you're a spirit in this body, in this vessel, for this time. What you're here to do is to love yourself and honor and love life. And how do you do that? You honor your temple. Not just your body but your mind, your spirit. And when you're given much and you're able to breathe, then you have to give to others.”   --   Thank you for joining us on The Daily Helping with Dr. Shuster. Subscribe to the show on Apple Podcasts, Stitcher, or Google Podcasts to download more food for the brain, knowledge from the experts, and tools to win at life.   Resources: tigerlilyfoundation.org Instagram: @tigerlily_foundation Instagram: @maimahkarmo

In this exciting episode, our very special guest is the wonderful Javacia Harris Bowser, an award-winning freelance journalist, columnist, and essayist and the founder of See Jane Write — a website and community for women who write and blog. Her writing focuses on women's issues, wealth and wellness. In this episode, we discuss Javacias experience with beating breast cancer at 38, and how to win at freelancing. Javacia transitioned from a 10-year career in teaching to her full-time, See Jane Write. According to a study that was recently published in Cancer Epidemiology, Biomarkers, & Prevention, a journal of the American Association for Cancer Research, "while breast cancer mortality rates have declined over the last few decades, Black women are still twice as likely to die from breast cancer compared to other ethnicities". This is according to the results of a study led by Robert Hines, associate professor of population health sciences at the College of Medicine. Javacia discussed the importance of good health care for Black and minority women and how she uses her voice to advocate through partners like the Tigerlily Foundation. After her diagnosis, Javacia also changed her lifestyle and her transition to freelancing also helped her cope with the demands of her cancer treatment schedule and needs, which took place during the COVID-19 pandemic. Tune in to listen in to this exciting episode of the Holistic Wealth Podcast with special guest, Javacica Harris Bowser. --- Support this podcast: https://anchor.fm/keisha-blair/support

This week's guest is a true changemaker and force for good in healthcare. Maimah Karmo, President & CEO of the Tigerlily Foundation joins the show to discuss how she's advocating and driving actionable solutions in our industry. Plus, she shares her love of Michael Jackson's Thriller album.

Join us today as we have special guest USOA Ms. North Carolina Vera Morris as she shares her story with us. Learn the importance of Breast Cancer Awareness and how it can affect anyone. Such an important topic and need to know advice. Vera received her Associates of Arts degree from Peace College in Raleigh, North Carolina, and a Bachelor of Arts degree in Speech Communication, from the University of Georgia. Vera fulfilled her lifelong dream of becoming Miss North Carolina USA in 1998. She was awarded the Miss Congeniality award at the televised, Miss USA 1998 pageant. In 2015, Vera became an Ambassador for Susan G. Komen, in which she would raise awareness about breast cancer, and speak at events. For a second year, Vera will be a Honorary Committee Member for Making Strides Against Breast Cancer, Charlotte NC, where she was marketing events for Breast Cancer Awareness Month and attending fundraiser events. She also is an Ambassador for Pretty In Pink Foundation, Raleigh, NC. She recently was a Panelist for Tigerlily Foundation's Patient Advocacy in Policy Change to End Health Disparities series. Vera's platform “Treasure Your Chest” was created based upon the numerous women her in life that have been impacted by breast cancer. Vera recently started a “Treasure Your Chest” blog that features stories from women and men impacted by breast cancer, that is found on her website www.veramorris.com. Vera is the reigning United States of America's Ms. 2021. She was awarded Ms. Congeniality by her fellow pageant sisters and placed in the Top 8 at the United States of America's Ms. 2021 National pageant in February in San Antonio, TX. Vera's message is very informative on so many levels. You are really going to enjoy! And always thank you for your support. May God bless you and stay safe. Don't forget to follow us on Facebook, Instagram, TicTok, and Twitter @YourUniqueSparkle to stay in tune to Healthy Tips, Inspirational Stories, and Mental Health. Download a FREE Ebook - 'Self Sabotage' - Reignite Your Sparkle https://designrr.site?i=jn7b&t=ad573f&f=1 https://uniquesparkle.samcart.com/products/becoming-your-true-authentic-self-course Feel free to comment or ask questions to YourUniqueSparkle@gmail.com --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Join us today as we have special guest USOA Ms. North Carolina Vera Morris as she shares her story with us. Learn the importance of Breast Cancer Awareness and how it can affect anyone. Such an important topic and need to know advice. Vera received her Associates of Arts degree from Peace College in Raleigh, North Carolina, and a Bachelor of Arts degree in Speech Communication, from the University of Georgia. Vera fulfilled her lifelong dream of becoming Miss North Carolina USA in 1998. She was awarded the Miss Congeniality award at the televised, Miss USA 1998 pageant. In 2015, Vera became an Ambassador for Susan G. Komen, in which she would raise awareness about breast cancer, and speak at events. For a second year, Vera will be a Honorary Committee Member for Making Strides Against Breast Cancer, Charlotte NC, where she was marketing events for Breast Cancer Awareness Month and attending fundraiser events. She also is an Ambassador for Pretty In Pink Foundation, Raleigh, NC. She recently was a Panelist for Tigerlily Foundation's Patient Advocacy in Policy Change to End Health Disparities series. Vera's platform “Treasure Your Chest” was created based upon the numerous women her in life that have been impacted by breast cancer. Vera recently started a “Treasure Your Chest” blog that features stories from women and men impacted by breast cancer, that is found on her website www.veramorris.com. Vera is the reigning United States of America's Ms. 2021. She was awarded Ms. Congeniality by her fellow pageant sisters and placed in the Top 8 at the United States of America's Ms. 2021 National pageant in February in San Antonio, TX. Vera's message is very informative on so many levels. You are really going to enjoy! And always thank you for your support. May God bless you and stay safe. Don't forget to follow us on Facebook, Instagram, TicTok, and Twitter @YourUniqueSparkle to stay in tune to Healthy Tips, Inspirational Stories, and Mental Health. Download a FREE Ebook - 'Self Sabotage' - Reignite Your Sparkle https://designrr.site?i=jn7b&t=ad573f&f=1 https://uniquesparkle.samcart.com/products/becoming-your-true-authentic-self-course Feel free to comment or ask questions to YourUniqueSparkle@gmail.com --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Go online to PeerView.com/HCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The CDK4 and 6 inhibitors have been game-changers in the management of metastatic HR+, HER2- breast cancer, and accumulating evidence is now showing that they may also provide substantial benefits to some patients in early-stage settings, especially as adjuvant therapy for patients at high risk for disease recurrence. Various novel agents are also emerging as additional options for patients with HR+ breast cancer, including selective estrogen receptor degraders (SERDs) and selective estrogen receptor modulators (SERMs). Rapid developments in the treatment of this subtype of breast cancer provide new hope for further improving outcomes, but they also complicate treatment selection and care decisions for diverse populations of patients with HR+ disease. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all patients with advanced and early-stage HR+ breast cancer, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Cite the rationale for use, mechanisms of action, and features of the various endocrine, targeted, and other therapy options for HR+ breast cancer, Evaluate the most recent efficacy, safety, predictive/prognostic markers, and other key findings from clinical trials assessing different endocrine, targeted, and other emerging therapies and combinations for HR+ breast cancer and the associated relevant practical considerations, Describe the relevant patient-, disease-, and treatment-related factors as well as promising prognostic/predictive markers that could direct selection of endocrine, targeted, and/or other therapies/combinations for patients with HR+ breast cancer, Integrate the latest endocrine, targeted, and/or other treatments/combinations into personalized management plans for eligible patients with HR+ breast cancer in the context of clinical practice or clinical trial participation, according to relevant evidence, best practice recommendations, prognostic/predictive factors, and patient needs and preferences, while addressing disparities in clinical care and research.

Go online to PeerView.com/HCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The CDK4 and 6 inhibitors have been game-changers in the management of metastatic HR+, HER2- breast cancer, and accumulating evidence is now showing that they may also provide substantial benefits to some patients in early-stage settings, especially as adjuvant therapy for patients at high risk for disease recurrence. Various novel agents are also emerging as additional options for patients with HR+ breast cancer, including selective estrogen receptor degraders (SERDs) and selective estrogen receptor modulators (SERMs). Rapid developments in the treatment of this subtype of breast cancer provide new hope for further improving outcomes, but they also complicate treatment selection and care decisions for diverse populations of patients with HR+ disease. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all patients with advanced and early-stage HR+ breast cancer, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Cite the rationale for use, mechanisms of action, and features of the various endocrine, targeted, and other therapy options for HR+ breast cancer, Evaluate the most recent efficacy, safety, predictive/prognostic markers, and other key findings from clinical trials assessing different endocrine, targeted, and other emerging therapies and combinations for HR+ breast cancer and the associated relevant practical considerations, Describe the relevant patient-, disease-, and treatment-related factors as well as promising prognostic/predictive markers that could direct selection of endocrine, targeted, and/or other therapies/combinations for patients with HR+ breast cancer, Integrate the latest endocrine, targeted, and/or other treatments/combinations into personalized management plans for eligible patients with HR+ breast cancer in the context of clinical practice or clinical trial participation, according to relevant evidence, best practice recommendations, prognostic/predictive factors, and patient needs and preferences, while addressing disparities in clinical care and research.

Go online to PeerView.com/HCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The CDK4 and 6 inhibitors have been game-changers in the management of metastatic HR+, HER2- breast cancer, and accumulating evidence is now showing that they may also provide substantial benefits to some patients in early-stage settings, especially as adjuvant therapy for patients at high risk for disease recurrence. Various novel agents are also emerging as additional options for patients with HR+ breast cancer, including selective estrogen receptor degraders (SERDs) and selective estrogen receptor modulators (SERMs). Rapid developments in the treatment of this subtype of breast cancer provide new hope for further improving outcomes, but they also complicate treatment selection and care decisions for diverse populations of patients with HR+ disease. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all patients with advanced and early-stage HR+ breast cancer, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Cite the rationale for use, mechanisms of action, and features of the various endocrine, targeted, and other therapy options for HR+ breast cancer, Evaluate the most recent efficacy, safety, predictive/prognostic markers, and other key findings from clinical trials assessing different endocrine, targeted, and other emerging therapies and combinations for HR+ breast cancer and the associated relevant practical considerations, Describe the relevant patient-, disease-, and treatment-related factors as well as promising prognostic/predictive markers that could direct selection of endocrine, targeted, and/or other therapies/combinations for patients with HR+ breast cancer, Integrate the latest endocrine, targeted, and/or other treatments/combinations into personalized management plans for eligible patients with HR+ breast cancer in the context of clinical practice or clinical trial participation, according to relevant evidence, best practice recommendations, prognostic/predictive factors, and patient needs and preferences, while addressing disparities in clinical care and research.

Go online to PeerView.com/EKR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) is an aggressive cancer that has historically been associated with particularly poor patient outcomes. Fortunately, the recent validation of immunotherapies in advanced and early disease settings and the continued emergence of new targeted therapy approaches have brought hope to a patient population for whom only limited options existed for many decades. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, provides the latest research updates and case-driven practical guidance on using novel treatment approaches that have been shown to improve outcomes in patients with TNBC or are showing great promise based on accumulating evidence. Recognizing and mitigating healthcare disparities in breast cancer clinical care and research related to TNBC and breast cancer more broadly is also discussed from the perspectives of both clinicians/researchers and patients/advocates. Upon completion of this accredited CE activity, participants should be better able to: Summarize the underlying disease biology, clinical characteristics, and current therapeutic options for TNBC, including immunotherapies and targeted therapies, Cite the most recent safety, efficacy, and biomarker evidence from clinical trials investigating validated and emerging treatments in TNBC, including immunotherapies and targeted treatment approaches, Incorporate immunotherapeutic and targeted agents into management plans for patients with TNBC considering the latest data, indications, guidance, disease stage/treatment setting, tumor features, and patient needs/preferences, and integrate optimized and individualized approaches to biomarker testing, treatment selection and sequencing, adverse event monitoring and management, and team-based care.

Go online to PeerView.com/EKR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) is an aggressive cancer that has historically been associated with particularly poor patient outcomes. Fortunately, the recent validation of immunotherapies in advanced and early disease settings and the continued emergence of new targeted therapy approaches have brought hope to a patient population for whom only limited options existed for many decades. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, provides the latest research updates and case-driven practical guidance on using novel treatment approaches that have been shown to improve outcomes in patients with TNBC or are showing great promise based on accumulating evidence. Recognizing and mitigating healthcare disparities in breast cancer clinical care and research related to TNBC and breast cancer more broadly is also discussed from the perspectives of both clinicians/researchers and patients/advocates. Upon completion of this accredited CE activity, participants should be better able to: Summarize the underlying disease biology, clinical characteristics, and current therapeutic options for TNBC, including immunotherapies and targeted therapies, Cite the most recent safety, efficacy, and biomarker evidence from clinical trials investigating validated and emerging treatments in TNBC, including immunotherapies and targeted treatment approaches, Incorporate immunotherapeutic and targeted agents into management plans for patients with TNBC considering the latest data, indications, guidance, disease stage/treatment setting, tumor features, and patient needs/preferences, and integrate optimized and individualized approaches to biomarker testing, treatment selection and sequencing, adverse event monitoring and management, and team-based care.

Go online to PeerView.com/EKR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) is an aggressive cancer that has historically been associated with particularly poor patient outcomes. Fortunately, the recent validation of immunotherapies in advanced and early disease settings and the continued emergence of new targeted therapy approaches have brought hope to a patient population for whom only limited options existed for many decades. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, provides the latest research updates and case-driven practical guidance on using novel treatment approaches that have been shown to improve outcomes in patients with TNBC or are showing great promise based on accumulating evidence. Recognizing and mitigating healthcare disparities in breast cancer clinical care and research related to TNBC and breast cancer more broadly is also discussed from the perspectives of both clinicians/researchers and patients/advocates. Upon completion of this accredited CE activity, participants should be better able to: Summarize the underlying disease biology, clinical characteristics, and current therapeutic options for TNBC, including immunotherapies and targeted therapies, Cite the most recent safety, efficacy, and biomarker evidence from clinical trials investigating validated and emerging treatments in TNBC, including immunotherapies and targeted treatment approaches, Incorporate immunotherapeutic and targeted agents into management plans for patients with TNBC considering the latest data, indications, guidance, disease stage/treatment setting, tumor features, and patient needs/preferences, and integrate optimized and individualized approaches to biomarker testing, treatment selection and sequencing, adverse event monitoring and management, and team-based care.

Go online to PeerView.com/HCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The CDK4 and 6 inhibitors have been game-changers in the management of metastatic HR+, HER2- breast cancer, and accumulating evidence is now showing that they may also provide substantial benefits to some patients in early-stage settings, especially as adjuvant therapy for patients at high risk for disease recurrence. Various novel agents are also emerging as additional options for patients with HR+ breast cancer, including selective estrogen receptor degraders (SERDs) and selective estrogen receptor modulators (SERMs). Rapid developments in the treatment of this subtype of breast cancer provide new hope for further improving outcomes, but they also complicate treatment selection and care decisions for diverse populations of patients with HR+ disease. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all patients with advanced and early-stage HR+ breast cancer, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Cite the rationale for use, mechanisms of action, and features of the various endocrine, targeted, and other therapy options for HR+ breast cancer, Evaluate the most recent efficacy, safety, predictive/prognostic markers, and other key findings from clinical trials assessing different endocrine, targeted, and other emerging therapies and combinations for HR+ breast cancer and the associated relevant practical considerations, Describe the relevant patient-, disease-, and treatment-related factors as well as promising prognostic/predictive markers that could direct selection of endocrine, targeted, and/or other therapies/combinations for patients with HR+ breast cancer, Integrate the latest endocrine, targeted, and/or other treatments/combinations into personalized management plans for eligible patients with HR+ breast cancer in the context of clinical practice or clinical trial participation, according to relevant evidence, best practice recommendations, prognostic/predictive factors, and patient needs and preferences, while addressing disparities in clinical care and research.

Go online to PeerView.com/HCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The CDK4 and 6 inhibitors have been game-changers in the management of metastatic HR+, HER2- breast cancer, and accumulating evidence is now showing that they may also provide substantial benefits to some patients in early-stage settings, especially as adjuvant therapy for patients at high risk for disease recurrence. Various novel agents are also emerging as additional options for patients with HR+ breast cancer, including selective estrogen receptor degraders (SERDs) and selective estrogen receptor modulators (SERMs). Rapid developments in the treatment of this subtype of breast cancer provide new hope for further improving outcomes, but they also complicate treatment selection and care decisions for diverse populations of patients with HR+ disease. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all patients with advanced and early-stage HR+ breast cancer, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Cite the rationale for use, mechanisms of action, and features of the various endocrine, targeted, and other therapy options for HR+ breast cancer, Evaluate the most recent efficacy, safety, predictive/prognostic markers, and other key findings from clinical trials assessing different endocrine, targeted, and other emerging therapies and combinations for HR+ breast cancer and the associated relevant practical considerations, Describe the relevant patient-, disease-, and treatment-related factors as well as promising prognostic/predictive markers that could direct selection of endocrine, targeted, and/or other therapies/combinations for patients with HR+ breast cancer, Integrate the latest endocrine, targeted, and/or other treatments/combinations into personalized management plans for eligible patients with HR+ breast cancer in the context of clinical practice or clinical trial participation, according to relevant evidence, best practice recommendations, prognostic/predictive factors, and patient needs and preferences, while addressing disparities in clinical care and research.

Go online to PeerView.com/HCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The CDK4 and 6 inhibitors have been game-changers in the management of metastatic HR+, HER2- breast cancer, and accumulating evidence is now showing that they may also provide substantial benefits to some patients in early-stage settings, especially as adjuvant therapy for patients at high risk for disease recurrence. Various novel agents are also emerging as additional options for patients with HR+ breast cancer, including selective estrogen receptor degraders (SERDs) and selective estrogen receptor modulators (SERMs). Rapid developments in the treatment of this subtype of breast cancer provide new hope for further improving outcomes, but they also complicate treatment selection and care decisions for diverse populations of patients with HR+ disease. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all patients with advanced and early-stage HR+ breast cancer, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Cite the rationale for use, mechanisms of action, and features of the various endocrine, targeted, and other therapy options for HR+ breast cancer, Evaluate the most recent efficacy, safety, predictive/prognostic markers, and other key findings from clinical trials assessing different endocrine, targeted, and other emerging therapies and combinations for HR+ breast cancer and the associated relevant practical considerations, Describe the relevant patient-, disease-, and treatment-related factors as well as promising prognostic/predictive markers that could direct selection of endocrine, targeted, and/or other therapies/combinations for patients with HR+ breast cancer, Integrate the latest endocrine, targeted, and/or other treatments/combinations into personalized management plans for eligible patients with HR+ breast cancer in the context of clinical practice or clinical trial participation, according to relevant evidence, best practice recommendations, prognostic/predictive factors, and patient needs and preferences, while addressing disparities in clinical care and research.

Go online to PeerView.com/SAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The number of different HER2-targeted agents and combinations in the treatment arsenal for early-stage and metastatic HER2-positive breast cancer continues to grow, offering more options for customizing the care plans for individual patients, but also making the clinical decisions about selection and sequencing of these therapies more complex. Many factors need to be considered to ensure that diverse populations of patients with HER2-positive breast cancer receive the best therapy at the right time. This activity based on a live web broadcast, developed in collaboration with top experts in HER2-positive breast cancer and in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Review the attributes, mechanisms of action, clinical roles, and rationale for use of HER2-targeted therapies for early-stage and advanced HER2-positive breast cancer, Analyze the latest safety and efficacy evidence on established and emerging HER2-targeted agents and combinations in the neoadjuvant and adjuvant settings in early breast cancer, including appropriate treatment selection and sequencing for patients or those with a high risk of recurrence with residual disease after neoadjuvant therapy, Evaluate validated, novel, and investigational HER2-targeted therapies and combinations for metastatic breast cancer, including newer treatment options showing promise in challenging patient subgroups (eg, patients with CNS metastases, low HER2 expression), Implement appropriate strategies for HER2 testing and integration of HER2-targeted therapies into personalized management plans for diverse patient populations with early and advanced/metastatic HER2-positive breast cancer either in the context of clinical practice or through enrollment in clinical trials.

Go online to PeerView.com/EKR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) is an aggressive cancer that has historically been associated with particularly poor patient outcomes. Fortunately, the recent validation of immunotherapies in advanced and early disease settings and the continued emergence of new targeted therapy approaches have brought hope to a patient population for whom only limited options existed for many decades. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, provides the latest research updates and case-driven practical guidance on using novel treatment approaches that have been shown to improve outcomes in patients with TNBC or are showing great promise based on accumulating evidence. Recognizing and mitigating healthcare disparities in breast cancer clinical care and research related to TNBC and breast cancer more broadly is also discussed from the perspectives of both clinicians/researchers and patients/advocates. Upon completion of this accredited CE activity, participants should be better able to: Summarize the underlying disease biology, clinical characteristics, and current therapeutic options for TNBC, including immunotherapies and targeted therapies, Cite the most recent safety, efficacy, and biomarker evidence from clinical trials investigating validated and emerging treatments in TNBC, including immunotherapies and targeted treatment approaches Incorporate immunotherapeutic and targeted agents into management plans for patients with TNBC considering the latest data, indications, guidance, disease stage/treatment setting, tumor features, and patient needs/preferences, and integrate optimized and individualized approaches to biomarker testing, treatment selection and sequencing, adverse event monitoring and management, and team-based care.

Go online to PeerView.com/SAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The number of different HER2-targeted agents and combinations in the treatment arsenal for early-stage and metastatic HER2-positive breast cancer continues to grow, offering more options for customizing the care plans for individual patients, but also making the clinical decisions about selection and sequencing of these therapies more complex. Many factors need to be considered to ensure that diverse populations of patients with HER2-positive breast cancer receive the best therapy at the right time. This activity based on a live web broadcast, developed in collaboration with top experts in HER2-positive breast cancer and in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Review the attributes, mechanisms of action, clinical roles, and rationale for use of HER2-targeted therapies for early-stage and advanced HER2-positive breast cancer, Analyze the latest safety and efficacy evidence on established and emerging HER2-targeted agents and combinations in the neoadjuvant and adjuvant settings in early breast cancer, including appropriate treatment selection and sequencing for patients or those with a high risk of recurrence with residual disease after neoadjuvant therapy, Evaluate validated, novel, and investigational HER2-targeted therapies and combinations for metastatic breast cancer, including newer treatment options showing promise in challenging patient subgroups (eg, patients with CNS metastases, low HER2 expression), Implement appropriate strategies for HER2 testing and integration of HER2-targeted therapies into personalized management plans for diverse patient populations with early and advanced/metastatic HER2-positive breast cancer either in the context of clinical practice or through enrollment in clinical trials.

Go online to PeerView.com/SAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The number of different HER2-targeted agents and combinations in the treatment arsenal for early-stage and metastatic HER2-positive breast cancer continues to grow, offering more options for customizing the care plans for individual patients, but also making the clinical decisions about selection and sequencing of these therapies more complex. Many factors need to be considered to ensure that diverse populations of patients with HER2-positive breast cancer receive the best therapy at the right time. This activity based on a live web broadcast, developed in collaboration with top experts in HER2-positive breast cancer and in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Review the attributes, mechanisms of action, clinical roles, and rationale for use of HER2-targeted therapies for early-stage and advanced HER2-positive breast cancer, Analyze the latest safety and efficacy evidence on established and emerging HER2-targeted agents and combinations in the neoadjuvant and adjuvant settings in early breast cancer, including appropriate treatment selection and sequencing for patients or those with a high risk of recurrence with residual disease after neoadjuvant therapy, Evaluate validated, novel, and investigational HER2-targeted therapies and combinations for metastatic breast cancer, including newer treatment options showing promise in challenging patient subgroups (eg, patients with CNS metastases, low HER2 expression), Implement appropriate strategies for HER2 testing and integration of HER2-targeted therapies into personalized management plans for diverse patient populations with early and advanced/metastatic HER2-positive breast cancer either in the context of clinical practice or through enrollment in clinical trials.

Go online to PeerView.com/SAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The number of different HER2-targeted agents and combinations in the treatment arsenal for early-stage and metastatic HER2-positive breast cancer continues to grow, offering more options for customizing the care plans for individual patients, but also making the clinical decisions about selection and sequencing of these therapies more complex. Many factors need to be considered to ensure that diverse populations of patients with HER2-positive breast cancer receive the best therapy at the right time. This activity based on a live web broadcast, developed in collaboration with top experts in HER2-positive breast cancer and in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Review the attributes, mechanisms of action, clinical roles, and rationale for use of HER2-targeted therapies for early-stage and advanced HER2-positive breast cancer, Analyze the latest safety and efficacy evidence on established and emerging HER2-targeted agents and combinations in the neoadjuvant and adjuvant settings in early breast cancer, including appropriate treatment selection and sequencing for patients or those with a high risk of recurrence with residual disease after neoadjuvant therapy, Evaluate validated, novel, and investigational HER2-targeted therapies and combinations for metastatic breast cancer, including newer treatment options showing promise in challenging patient subgroups (eg, patients with CNS metastases, low HER2 expression), Implement appropriate strategies for HER2 testing and integration of HER2-targeted therapies into personalized management plans for diverse patient populations with early and advanced/metastatic HER2-positive breast cancer either in the context of clinical practice or through enrollment in clinical trials.

Go online to PeerView.com/EKR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) is an aggressive cancer that has historically been associated with particularly poor patient outcomes. Fortunately, the recent validation of immunotherapies in advanced and early disease settings and the continued emergence of new targeted therapy approaches have brought hope to a patient population for whom only limited options existed for many decades. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, provides the latest research updates and case-driven practical guidance on using novel treatment approaches that have been shown to improve outcomes in patients with TNBC or are showing great promise based on accumulating evidence. Recognizing and mitigating healthcare disparities in breast cancer clinical care and research related to TNBC and breast cancer more broadly is also discussed from the perspectives of both clinicians/researchers and patients/advocates. Upon completion of this accredited CE activity, participants should be better able to: Summarize the underlying disease biology, clinical characteristics, and current therapeutic options for TNBC, including immunotherapies and targeted therapies, Cite the most recent safety, efficacy, and biomarker evidence from clinical trials investigating validated and emerging treatments in TNBC, including immunotherapies and targeted treatment approaches Incorporate immunotherapeutic and targeted agents into management plans for patients with TNBC considering the latest data, indications, guidance, disease stage/treatment setting, tumor features, and patient needs/preferences, and integrate optimized and individualized approaches to biomarker testing, treatment selection and sequencing, adverse event monitoring and management, and team-based care.

Go online to PeerView.com/SAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The number of different HER2-targeted agents and combinations in the treatment arsenal for early-stage and metastatic HER2-positive breast cancer continues to grow, offering more options for customizing the care plans for individual patients, but also making the clinical decisions about selection and sequencing of these therapies more complex. Many factors need to be considered to ensure that diverse populations of patients with HER2-positive breast cancer receive the best therapy at the right time. This activity based on a live web broadcast, developed in collaboration with top experts in HER2-positive breast cancer and in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Review the attributes, mechanisms of action, clinical roles, and rationale for use of HER2-targeted therapies for early-stage and advanced HER2-positive breast cancer, Analyze the latest safety and efficacy evidence on established and emerging HER2-targeted agents and combinations in the neoadjuvant and adjuvant settings in early breast cancer, including appropriate treatment selection and sequencing for patients or those with a high risk of recurrence with residual disease after neoadjuvant therapy, Evaluate validated, novel, and investigational HER2-targeted therapies and combinations for metastatic breast cancer, including newer treatment options showing promise in challenging patient subgroups (eg, patients with CNS metastases, low HER2 expression), Implement appropriate strategies for HER2 testing and integration of HER2-targeted therapies into personalized management plans for diverse patient populations with early and advanced/metastatic HER2-positive breast cancer either in the context of clinical practice or through enrollment in clinical trials.

Go online to PeerView.com/SAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The number of different HER2-targeted agents and combinations in the treatment arsenal for early-stage and metastatic HER2-positive breast cancer continues to grow, offering more options for customizing the care plans for individual patients, but also making the clinical decisions about selection and sequencing of these therapies more complex. Many factors need to be considered to ensure that diverse populations of patients with HER2-positive breast cancer receive the best therapy at the right time. This activity based on a live web broadcast, developed in collaboration with top experts in HER2-positive breast cancer and in partnership with the Tigerlily Foundation, focuses on the practicalities of delivering equitable care and individualized treatment to all, informed by the latest science, guidelines, and patient needs. Upon completion of this accredited CE activity, participants should be better able to: Review the attributes, mechanisms of action, clinical roles, and rationale for use of HER2-targeted therapies for early-stage and advanced HER2-positive breast cancer, Analyze the latest safety and efficacy evidence on established and emerging HER2-targeted agents and combinations in the neoadjuvant and adjuvant settings in early breast cancer, including appropriate treatment selection and sequencing for patients or those with a high risk of recurrence with residual disease after neoadjuvant therapy, Evaluate validated, novel, and investigational HER2-targeted therapies and combinations for metastatic breast cancer, including newer treatment options showing promise in challenging patient subgroups (eg, patients with CNS metastases, low HER2 expression), Implement appropriate strategies for HER2 testing and integration of HER2-targeted therapies into personalized management plans for diverse patient populations with early and advanced/metastatic HER2-positive breast cancer either in the context of clinical practice or through enrollment in clinical trials.

Go online to PeerView.com/EKR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) is an aggressive cancer that has historically been associated with particularly poor patient outcomes. Fortunately, the recent validation of immunotherapies in advanced and early disease settings and the continued emergence of new targeted therapy approaches have brought hope to a patient population for whom only limited options existed for many decades. This PeerView educational activity, based on a recent web broadcast and produced in partnership with the Tigerlily Foundation, provides the latest research updates and case-driven practical guidance on using novel treatment approaches that have been shown to improve outcomes in patients with TNBC or are showing great promise based on accumulating evidence. Recognizing and mitigating healthcare disparities in breast cancer clinical care and research related to TNBC and breast cancer more broadly is also discussed from the perspectives of both clinicians/researchers and patients/advocates. Upon completion of this accredited CE activity, participants should be better able to: Summarize the underlying disease biology, clinical characteristics, and current therapeutic options for TNBC, including immunotherapies and targeted therapies, Cite the most recent safety, efficacy, and biomarker evidence from clinical trials investigating validated and emerging treatments in TNBC, including immunotherapies and targeted treatment approaches Incorporate immunotherapeutic and targeted agents into management plans for patients with TNBC considering the latest data, indications, guidance, disease stage/treatment setting, tumor features, and patient needs/preferences, and integrate optimized and individualized approaches to biomarker testing, treatment selection and sequencing, adverse event monitoring and management, and team-based care.

In this episode, I interview Debora Barton, MD, and we discuss Carisma Therapeutics (CAR-T, CAR-M, Macrophage, and Cancer Therapies) as well as her new board role at Tigerlily Foundation.

In this series finale, we meet Maimah Karmo, President, and CEO of the Tigerlily Foundation, and learn about her journey to end disparities for young breast cancer patients of color. If you like this series, be sure to subscribe, leave a rating, a review, share on social media, and please tell your community to check it out. Your voice matters. Tell us your story in your voice and give us your feedback about the series by leaving us a good old-fashioned voicemail at (855) AUDIO66 (283-4666.) And don’t forget to join the #BCSM weekly tweet chat live every Monday at 9pm/ET on Twitter.

In this series finale crossover episode, we meet Maimah Karmo, President, and CEO of the Tigerlily Foundation, and learn about her journey to end disparities for young breast cancer patients of color. If you like this series, be sure to subscribe, leave a rating, a review, share on social media, and please tell your community to check it out. Your voice matters. Tell us your story in your voice and give us your feedback about the series by leaving us a good old-fashioned voicemail at (855) AUDIO66 (283-4666.) And don’t forget to join the #BCSM weekly tweet chat live every Monday at 9pm/ET on Twitter.

Join Co-hosts Sheila McGlown and Lisa Laudico for a conversation with Maimah Karmo, founder of the Tigerlily Foundation along with Christine Hodgdon and Julia Maues, co-founders of GRASP and the #PullUpASeat initiative. We are pleased to release this episode on the eve of Maimah's groundbreaking keynote and session at the 2020 San Antonio Breast Cancer Symposium, the largest breast cancer symposium in the world, where she is co-presenting with the AACR on Setting the Stage for Health Equity, Collaboration, and Partnership. We find out what specifically has happened in the year since the launch of the #InclusionPledge and find out more about the #KnowMoreDisparities and #PullUpASeat initiatives. This is an extraordinary discussion on inclusion, disparities, allyship, privilege, stigmas, and the power of the individual. Check out our blog and episode notes on our website, www.ourmbclife.org. We are found on Facebook, Twitter, and Instargram @ourmbclife.

Join us as we revisit our inaugural episode with Maimah Karmo of the Tigerlily Foundation. The #inclusionpledge initiative was started when our Trailblazer series co-host and the founder of Angel In Disquise, Inc, Jersi Baker, raised her voice at a conference asking why no one looked like her on stage even when the discussion was on racial disparities in healthcare for people living with MBC. From there, the TigerLilly Foundation’s Maimah Karmo in partnership with the founders of GRASP, Christine Hodgdon and Julia Maues and many others, developed the #inclusionpledge to get organizations and individuals to commit to taking real action to change these disparities. We will catch up with Maimah, Christine and Julia later this month but we wanted to re-release our inaugural podcast with Maimah since it is so very relevant still. Check out our blog and episode notes on our website, www.ourmbclife.org. We are found on FAcebook, Twitter, and Instagram @ourmbclife.

Today I am sitting down with Tania Koulakian who is the programs and digital media manager from The Tigerlily Foundation. We are discussing their unwavering commitment to take action, how they show up in really powerful ways and game-changing ways. We are also chatting about spirituality and how that can help us to thrive! Tania shares a glimpse into the Tigerlily’s 2020 virtual spirit retreat! Join the retreat here - https://www.tigerlilyfoundation.org/2020-virtual-spirit-retreat/Topics discussed in this episode:The power of spirituality and how it can affect how we thriveThe importance of surrounding yourself with a foundation that takes action and makes an impactThe lapse in care for young women going through breast cancerWhy we need to advocate, educate, empower, and support young women going through and after breast cancer. Which is exactly what the Tigerlily Foundation doesHow the Tigerlily foundation came to beKey takeaways:How to connect with your spiritual path and why the virtual retreat is the perfect timeHow you can join and help to take inspired actionsMy journey on getting connects with the Tigerlily foundationAction step:Become informed and empowered about your healthThanks so much for listening!Important Announcements: If you haven’t downloaded our FREE 3 Vital Steps to THRIVE after BC mini-course yet, download it now! It breaks prevention and thrivership down into the 3 vital steps you need to focus on, cuts through the confusion of all the conflicting information on the interwebs, and provides clear and actionable information so that you feel confident in your prevention plan. You will love it!If you’re looking for an amazing community to connect with and a group of women that are all on their journey to healing and want to feel confident in their prevention plan, join our Breast Cancer Babes Community on Facebook.Connect with me over on Instagram, @iambreastcancerthriver. It would also mean so much if you would leave us a rating or a review at any podcast platform that you’re listening to us on.Links I mention in this episode:Mukta Cork Yoga Mat2020 Virtual Spirit RetreatWhere you can find Tania and the Tigerlily Foundation:Tania’s InstagramTigerlily Foundation’s InstagramTigerlily Foundation’s WebsiteTigerlily Foundation’s TwitterTigerlily Foundation’s FacebookTigerlily Foundation’s 5KMy Life Is My Legacy

Today on the show, another Wayback Machine throwback episode with my dear friend and fellow survivor advocate Maimah Karmo, Maimah an author, speaker, coach, podcaster, manifestor, convener, Founder/CEO of the Tigerlily Foundation and, well, — she's a unicorn. Basically, she's just a unicorn so let's just leave it at then. Join us as we take a trip down memory lane to a time before iPhones, Android, Facebook, Twitter, and the original Kung Fu Panda. Yes, I am talking about 2007 and the dawn of the young adult cancer movement. From Liberian refugee to misdiagnosed triple-negative breast cancer patient, to self-proclaimed "chemo-induced nonprofit founder," Maimah has been a dominant voice speaking out on the issues of healthcare disparities and invisible suffering in the black community. There's pretty much nothing Maimah can't do — and you're about to understand why. Enjoy the show. Visit https://www.tigerlilyfoundation.org for more information.

Maimah Karmo is the Founder/CEO of the Tigerlily Foundation and a fourteen-year survivor of breast cancer. As a leader in the women's health and disparities field, she works on with local, national and global health, policy, advocacy organizations to transform the lives of girls and women. She has been featured on Fox 5, ABC 7, CBS, the Oprah Winfrey Show, OWN, Good Morning America, the Today Show and more. Her TED talk – “Leading Through Surrender to Soul Purpose” – was powerfully received. Maimah is a life coach, hosts The Pure Bliss podcast and hosts the “Manifest” events to inspire people to live the life they were born to manifest. What she shared during our interview, will inspire you to surrender to your purpose.

Maimah Karmo is the Founder/CEO of Tigerlily Foundation. On February 28, 2006, Maimah was diagnosed with Stage 2 breast cancer. She had no family history and was 32-years old. While undergoing her second round of chemotherapy, she vowed that if she survived, she would create an organization to educate, empower, advocate for and support young women affected by breast cancer. Tigerlily Foundation was born. Join us to hear her fascinating story and learn about the impact of cancer on young women. Breast Friends Radio Radio Show is broadcast live at Friday's at 1PM ET on W4CS – The Cancer Support Network (www.w4cs.com) part of Talk 4 Radio (www.talk4radio.com) on the Talk 4 Media Network (www.talk4media.com). This podcast is also available on Talk 4 Podcasting (www.talk4podcasting.com).

I am pleased to introduce my guest this week Maimah Karmo. She is the Founder/CEO of the Tigerlily Foundation (Tigerlily) and a thirteen-year survivor of breast cancer. On February 28, 2006, at 4:45 p.m., Maimah was diagnosed with Stage 2 breast cancer. She had no family history and was 32-years old. While undergoing her second round of chemotherapy, she made a promise to God that if she survived, she would create an organization to educate, empower, advocate for and support young women affected by breast cancer. After her second treatment, Tigerlily Foundation was born. Tigerlily is a national organization, with hundreds of volunteers nationwide, providing breast health, wellness and transformational programs to young women.

Guest Host Maimah Karmo, Founder and President of Tigerlily Foundation, engages in real talk about MBC with the Founder of Angel in Disguise, Angela Baker. This is a Charlotte-based organization providing transportation needs for breast cancer patients in treatment. Angela is living with metastatic breast cancer and shares her story about creating purpose in her life. Visit her website at http://angelindisguiseinc.org/.

This week's episode of the 180º of Impact podcast features Matt Scott's conversation with Maimah Karmo, the founder and CEO of Tigerlily Foundation and host of The Pure Bliss Show podcast. Follow Maimah on Twitter @Maimah and visit www.maimah.com for more. For more on 180º of Impact, visit www.lets.care and follow @LetsYouCare on social media. --- Send in a voice message: https://anchor.fm/letsyoucare/message

Author, speaker, nonprofit founder Maimah Karmo shares her inspiring life story and how she manifests bliss in her work and life. Maimah is the founder and CEO of the Tigerlily Foundation and a 10-year survivor of breast cancer. Find Maimah: http://maimah.com https://twitter.com/maimah?lang=en https://www.instagram.com/maimahkarmo/ Awesome Women Entrepreneurs:  https://awesomewomen.org/

Maimah Karmo is an author, philanthropist, and Founder and CEO of the Tigerlily Foundation. Over the last 10 years, Maimah has transformed herself from being a 32 year old mother with a young child and a diagnosis of breast cancer to an inspiration, guiding others in being fearless in transcending any life circumstance into an opportunity for personal evolution and bliss. For more information on Maimah and her work, visit www.MaimahKarmo.com.

Maimah Karmo is a powerhouse like the Eartha Kitt of our ages in the spiritual realm of self-care and manifesting better health. Listen in for her three tips and a bonus one for manifesting your bliss. On her website maimahkarmo.com, she says "I am Maimah Karmo. I am a soul-purpose seeker, philanthropist, author, mother, God-lover and all around bad ass. I am also the Founder and CEO of the Tigerlily Foundation and a 10-year survivor of breast cancer." Upcoming events: http://www.maimahkarmo.com/i-manifest-bliss-june/

BOOK: Thriving in the Workplace with Autoimmune Disease: Know Your Rights, Resolve Conflict, and Reduce Stress   http://amzn.to/2hcIKqP  200 High Vibration Foods Shopping List: http://learntruehealth.com/vibelist Limited Number of FREE BOOKS! http://learntruehealth.com/vibe Free $69 value 3-video course on raising your vibration! http://learntruehealth.com/reboot   Autoimmune Diseases http://learntruehealth.com/autoimmune-diseases/ Autoimmune Diseases: Thriving In The Workplace Autoimmune diseases are hard to detect, and some of them are incurable. Dealing with this health condition is a challenge in itself. Having to worry about how to survive in society such as the workplace is an even more significant obstacle to hurdle. My guest, Holly Bertone is no stranger to this situation. In fact, it empowered her to use her experience to help other people cope with autoimmune diseases. Transitioning Stage Holly Bertone has always been active during her teenage years and in her 20s. However, like many young people, she was a junkaholic who enjoyed sweets too much. Resolving to have a better lifestyle, Holly Bertone transitioned in her 30s and got into fitness. She was active in mountain bike races, swimming and running. Consequently, Holly Bertone’s diet improved. She still enjoyed sweets but consumed it in moderation. Diagnosed With Breast Cancer Thinking that her healthier lifestyle drove her further away from illnesses and diseases, Holly Bertone couldn’t be more wrong. On her 39th birthday, she got a gift she didn’t expect — breast cancer. Before the doctor breaking the news to her, Holly Bertone recalled that she initially felt a lump as she rolled in bed one morning. It took two months of tests before Holly Bertone’s doctor dropped the bomb. Life In Remission It’s hard when you find out you have cancer, but as the saying goes, ‘Life goes on.’ And that’s precisely what Holly Bertone did. Ten days after her cancer treatment ended, she got married. However, the ordeal wasn’t over. Even after cancer treatment, Holly Bertone wasn’t getting better. Some of Holly Bertone’s friends survived breast cancer and were running marathons, while Holly Bertone could barely get out of bed. “I picked an aggressive treatment. But in hindsight, I wish I looked for other treatments first, especially nutrition.” Diagnosed With Hashimoto’s Six years ago, Holly Bertone complained that she was still feeling sick all the time. Doctors initially did not take Holly Bertone seriously because this was a year after her successful cancer treatment ended. Hence, the testing dragged on and on until doctors found out Holly Bertone has Hashimoto’s disease. Hashimoto’s disease is an autoimmune thyroid condition. According to the Mayo Clinic, Hashimoto’s disease primarily affects middle-aged women. However, it can also occur in men and women of any age, and in children as well. Furthermore, it is the most common cause of hypothyroidism in the United States. Coping with Hashimoto’s Autoimmune diseases can’t be cured immediately, and it indeed can’t be cured overnight by taking a lot of drugs. Holly Bertone’s case was no exception. Everyday was a constant struggle. “I was still going to allopathic doctors at that time who told me I have a hypothyroid disease. Hence, I took a lot of medicines,” recalls Holly Bertone. “My health got worse. I had migraines, brain fog, cognition issues, joint pains and chronic fatigues for five years.” The Myers Way Discovering The Autoimmune Solution book by Dr. Amy Myers was Holly Bertone’s saving grace. The book expounds on the causes of autoimmune diseases and how to reverse it naturally through diet and lifestyle changes. A New York Times bestseller, Dr. Myers has helped thousands of people suffering from autoimmune diseases. The book provides a step-by-step process towards helping your body improve in a month. “I followed her ‘Myers Way’ autoimmune protocol. I cut gluten entirely, as well as processed foods and sugar. A week later, I got rid of dairy,” said Holly Bertone. “The more foods I started to eliminate and the cleaner I ate, my health improved.” Natural Living Holly Bertone’s battle with Hashimoto’s wasn’t limited to food. Bent on making her living environment as healthy as possible, she eventually got rid of all cleaning products that had harmful ingredients. Eventually developing her line of natural organic products for the home, Holly Bertone proudly only uses the best natural ingredients for her products. Her line has also expanded to making all-natural beauty products as well. “I first got rid of harmful cleaning products. Then I learned how to make my own non-toxic cleaning products and natural beauty products,” Holly Bertone said. “It was a month before I noticed significant changes.” My Mommy Has Cancer Book If cancer is hard for the person it was diagnosed with, it is hard for family members, too. Children are affected the most. Hence, this book was written to help both the parents and children process their feelings about the dreaded Big C. The book encourages parent and child to open the lines of communication about everything concerning cancer like chemotherapy, hair loss, surgery and much more. Each little topic has a break-out box that parents go over with their child to help them open up about how they feel. “My book is for elementary kids. My stepson helped me write it. He was seven years old when I was diagnosed with cancer,” said Holly Bertone. “He and another son of a survivor helped do the illustrations. It goes through the changes that a child sees when his parent has cancer.” Thriving In The Workplace If things in the homefront are challenging enough, Holly Bertone hurdled another situation at her workplace. Nowadays, it is hard to find companies who genuinely empathize with employees suffering from autoimmune diseases and other illnesses. You see, Holly Bertone worked for a federal government agency. For the past two years, Holly Bertone’s management has been very understanding, knowing she has Hashimoto’s disease and chronic fatigue. However, when the management changed, the new team was not accommodating at all. Consequently, Holly Bertone had to get a lot of paperwork to justify her disability. “Some laws covered my condition, but there was a lot of retributions against me. The new management was not happy that I was asking for minor accommodations regarding my health,” said Holly Bertone. One night, Holly Bertone was so sick, that she barely held it together. Her health was failing, and Holly Bertone’s doctor wanted her to get treatment. “I went to the doctor once, and the manager was not happy that I went to the appointment even if I had 480 hours of approved leaves legally covered. The top management rescinded it,” Holly Bertone recalls. After four to five months of declining health and stress, Holly Bertone made the difficult decision of resigning from her job that paid a hefty salary. However, treating her experience as a blessing in disguise, Holly Bertone decided to write a book to educate individuals with autoimmune diseases on their legal and disability rights in the workplace. “The Job Accommodation Network is a non-profit organization under the Department of Labor,” said Holly Bertone. “They can’t endorse my book, but they helped me gather info for accuracy. Their website also has a lot of good resources for people with disabilities.” Pink Fortitude Website Holly Bertone believes that the essence of everything that she writes about is taking whatever life hands her and making the world a better place because of it. Her yearning to help people is why she also put up her website called Pink Fortitude. Pink Fortitude aims to help people suffering from cancer and autoimmune diseases. The website promotes a healthy and natural lifestyle through food, cleaning products and much more. “I have faced death so many times. I don’t know when my last day is going to be. So I encourage people to strive to live life everyday with fortitude, regardless of what life hands you,” said Holly Bertone. Holly Bertone, CNHP, PMP, is a health entrepreneur, author, and advocate. She is the President and CEO of Pink Fortitude, LLC and runs the healthy living website pinkfortitude.com. Holly Bertone is a breast cancer and Hashimoto’s survivor and turned these two significant health challenges into a passion for helping others. She inspires others with her quick wit, brutal honesty, and simple ways to be healthy in real life. Holly Bertone is a Certified Natural Health Professional, a Certified Essential Oils Coach, and is enrolled in a Naturopathic Doctorate program. She holds a Master’s Degree from Johns Hopkins University, a Bachelor’s Degree from Elizabethtown College, and is a Project Management Professional (PMP). Her accolades include: 2016 Speaker at the Healing Hashimoto’s Summit 2015 Inspire Award from the Tigerlily Foundation 2015 Rookie of the Year Health Activist Finalist for WEGO Health 2014 Woman of the Year from the National Association for Professional Women Accepted into the National Cancer Survivor’s Day Speakers Bureau Ambassador for the Tigerlily Foundation and the National Breast Center Foundation Holly Bertone is passionate about reaching out to cancer and autoimmune survivors, and also volunteers for organizations supporting our military veterans. In her free time, she loves to garden and hit flea markets and yard sales. She is married to a retired Green Beret, is a stepmother, and lives in Alexandria, VA. Get Connected With Holly Bertone: Official Website Facebook Youtube Twitter Instagram  Pinterest Recommended Readings by Holly Bertone Urban Monk by Pedram Shoji   Books by Holly Bertone Thriving In The Workplace   The Links You Are Looking For: 200 High Vibration Foods Shopping List: http://learntruehealth.com/vibelist Limited Number of FREE BOOKS! http://learntruehealth.com/vibe Free $69 value 3-video course on raising your vibration! http://learntruehealth.com/reboot ------------------------------------------------------------------------------- Do you have a blood sugar issue? I can help you achieve healthy, normal and balanced blood sugar naturally! Visit BloodSugarCoach.com for your free 30min coaching call with Ashley James! http://www.BloodSugarCoach.com ------------------------------------------------------------------------------- Become A Health Coach Learn More About The Institute for Integrative Nutrition's Health Coaching Certification Program by checking out these four resources: 1) Integrative Nutrition's Curriculum Guide: http://geti.in/2cmUMxb 2) The IIN Curriculum Syllabus: http://geti.in/2miXTej 3) Module One of the IIN curriculum: http://geti.in/2cmWPl8 4) Get three free chapters of Joshua Rosenthal's book: http://geti.in/2cksU87 Watch my little video on how to become a Certified Health Coach! https://www.youtube.com/watch?v=CDDnofnSldI ------------------------------------------------------------------------------- If this episode made a difference in your life, please leave me a tip in the virtual tip jar by giving my podcast a great rating and review in iTunes! http://bit.ly/learntruehealth-itunes Thank you! Ashley James http://bit.ly/learntruehealth-itunes ------------------------------------------------------------------------------- Enjoyed this podcast episode? Visit my website Learn True Health with Ashley James so you can gain access to all of my episodes and more! LearnTrueHealth.com http://learntruehealth.com ------------------------------------------------------------------------------- Need Help Ordering The Right Supplements For You? Visit TakeYourSupplements.com, and a FREE health coach will help you! http://takeyoursupplements.com ------------------------------------------------------------------------------- Learn How To Achieve Optimal Health From Naturopathic Doctors! Get Learn True Health's Seven-Day Course For FREE! Visit go.learntruehealth.com http://go.learntruehealth.com/gw-oi ------------------------------------------------------------------------------- I made a low-carb, gluten-free cookbook just for you! Download your FREE copy today! Visit learntruehealth.com/free-health-cookbook http://learntruehealth.com/free-health-cookbook ------------------------------------------------------------------------------- Join Learn True Health's Facebook community group! Visit https://www.facebook.com/groups/LearnTrueHealth or search Learn True Health on Facebook! ------------------------------------------------------------------------------- Follow the Learn True Health podcast on social media! Share with your friends and spread the word! Let's all get healthier & happier together! Learn True Health - Facebook: https://www.facebook.com/2LearnTrueHealth Learn True Health - Twitter: https://twitter.com/learntruehealth Learn True Health - Medium: https://medium.com/@unstoppable_ashley Learn True Health - Pinterest: https://www.pinterest.com/healthpodcast Learn True Health - YouTube: http://bit.ly/LTH-YouTube-Subscribe ------------------------------------------------------------------------------- Facebook: https://www.facebook.com/2LearnTrueHealth Twitter: https://twitter.com/learntruehealth Medium: https://medium.com/@unstoppable_ashley Pinterest: https://www.pinterest.com/healthpodcast YouTube: http://bit.ly/LTH-YouTube-Subscribe Music: bensound.com SEO and Marketing by BraveSEOMarketing.com

Join us on the latest podcast episode of Tigerlily Foundation​'s MY LIFE Matters as Host, Erin, chats with Lisa Quinn about how to get busy living after a stage 4 cancer diagnosis.

Available on iTunes Join us on the latest podcast episode of the Tigerlily Foundation​'s MY LIFE Matters as Host, Erin McCarthy Azuse​ chats with Kelli Parker, a fierce advocate, loving mother, and beloved member of the MBC community. #MBC #MYLIFE #MYLIFEMATTERS #TIGERLILYFOUNDATION #MBC #METS #METASTATIC #PODCAST #CANCERPODCAST #CONNECT #TLF #METSMONDAY #IAMSUSAN #STAGE4 #STAGEIV #DONTIGNORESTAGE4 #INSPIRATION #KELLI

Ken Rochon and Sharon Frame introduce and speak with our phenomenal surprise guests for today, Maimah Karmo is the Founder and CEO of Tigerlily Foundation and a ten year survivor of breast cancer. She speaks about her life journey fighting with breast cancer and her inspiration to start her foundation. She also shares about her calling I MANIFESTED BLISS. The conversation leads to speaking with our next awesome guest speaker, Steve Akinboro, Ex-Executive Vice President of Domino's Pizza sharing his LIFE JOURNEY WITH A MESSAGE. Steve talks about his 50 messages from his life's journey and his book 50 Promises. Steve talks about how he started his life journey doing menial grunge work like cleaning bathrooms at McDonald and how because of his impeccable work ethic, he rose rapidly through the managerial ranks in the company.

Ken Rochon and Sharon Frame introduce and speak with our phenomenal surprise guests for today, Maimah Karmo is the Founder and CEO of Tigerlily Foundation and a ten year survivor of breast cancer. She speaks about her life journey fighting with breast cancer and her inspiration to start her foundation. She also shares about her calling I MANIFESTED BLISS. The conversation leads to speaking with our next awesome guest speaker, Steve Akinboro, Ex-Executive Vice President of Domino's Pizza sharing his LIFE JOURNEY WITH A MESSAGE. Steve talks about his 50 messages from his life's journey and his book 50 Promises. Steve talks about how he started his life journey doing menial grunge work like cleaning bathrooms at McDonald and how because of his impeccable work ethic, he rose rapidly through the managerial ranks in the company.

Today's interview is with Maimah Karmo. Maimah is a mother, philanthropist, author, advocate, cancer warrior, magazine publisher, life coach, entrepreneur, badass and unicorn. Maimah's story began in Liberia, West Africa, where she was born. After surviving two wars in Liberia, during a third coup d'état, she fled to the United States at 15 years old, when her father put her on a plane, alone, to avoid persecution due to the war. She worked her way through college and created her version of the American Dream. Maimah was raising a beautiful 3-year old when she was diagnosed with aggressive breast cancer in 2006. She had no family history and was 32-years old. While in treatment, Maimah made a promise to God that if she survived, she would create an organization to educate, empower, advocate for and support young women affected by breast cancer. Her promise became the Tigerlily Foundation, which educates, advocates for, empowers and supports young women, before, during and after breast cancer. She is also... See acast.com/privacy for privacy and opt-out information.

We got cozy and had a TRUE conversation about preventing a life of burn out and disease, and living aligned with our soul’s purpose.  This week we are joined by Maimah Karmo who is the Founder of Tigerlily Foundation and a ten year survivor of breast cancer. Learn more.

Transforming adversity into triumph with Holly Bertone. Holly Bertone, CNHP, PMP President and CEO of Pink Fortitude, LLC Holly Bertone, CNHP, PMP, is an author, blogger, healthy living advocate, and breast cancer and Hashimoto's survivor. She is the President and CEO of Pink Fortitude, LLC. Holly is a Certified Natural Health Professional and is enrolled in a Naturopathic Doctorate program. She holds a Masters Degree from Johns Hopkins University, a Bachelor's Degree from Elizabethtown College, and is a Project Management Professional (PMP). Her accolades include: 2016 Speaker at the Healing Hashimoto's Summit 2015 Inspire Award from the Tigerlily Foundation 2015 Rookie of the Year Health Activist Finalist for WEGO Health 2014 Woman of the Year from the National Association for Professional Women Accepted into the National Cancer Survivor's Day Speakers Bureau Ambassador for the Tigerlily Foundation and the National Breast Center Foundation Holly is passionate about reaching out to breast cancer survivors, and also volunteers for organizations supporting our military veterans. In her free time, she loves to garden, and hit flea markets and yard sales. Holly is married to a retired Green Beret, is a stepmother, and lives in Alexandria, VA. Contact: holly@pinkfortitude.com Web: https://pinkfortitude.com Facebook: https://www.facebook.com/coconutheadsurvivalguide Twitter: https://twitter.com/PinkFortitude Pinterest: https://www.pinterest.com/pinkfortitude/ Instagram: https://www.instagram.com/pinkfortitude/

Maimah Karmo was a 32-year-old single mother when she was diagnosed with breast cancer. During her treatment, many aspects of her personal and professional life fell apart. Rather than be a victim, Maimah chose to be the victor! She founded the Tigerlily Foundation and Bliss Magazine, has been a guest on the Oprah Winfree, and has helped pass a bill in Congress to support the research and treatment of Breast Cancer. She and I had an amazing conversation about life. Listen as I explain more: Listen on iTunes or Listen to/download this episode here: Maimah S. Karmo: Her book: Fearless: Awakening to My Life's Purpose Through Breast Cancer Her foundation: Tigerlily Foundation Her magazine: Bliss Magazine On Twitter: @Maimah On Facebook: Maimah Karmo: Author - Fearless Mentioned in this show: Worry No More! book Download: Affirmations for Abundant Living LIAM Team Life Coaching Community Subscription/Social Links: Subscribe on iTunes! Subscribe on Stitcher Radio! Watch on YouTube! LIAM on Twitter: @LifeIs262 LIAM on Facebook / LifeIsAMarathon Subscribe to the LIAM Mailing List www.BruceVanHorn.com Bruce Van Horn on Twitter Bruce Van Horn on Facebook    

Maimah Karmo was a 32-year-old single mother when she was diagnosed with breast cancer. During her treatment, many aspects of her personal and professional life fell apart. Rather than be a victim, Maimah chose to be the victor! She founded the Tigerlily Foundation and Bliss Magazine, has been a guest on the Oprah Winfree, and has helped pass a bill in Congress to support the research and treatment of Breast Cancer. She and I had an amazing conversation about life. Listen as I explain more: Listen on iTunes or Listen to/download this episode here: Maimah S. Karmo: Her book: Fearless: Awakening to My Life's Purpose Through Breast Cancer Her foundation: Tigerlily Foundation Her magazine: Bliss Magazine On Twitter: @Maimah On Facebook: Maimah Karmo: Author - Fearless Mentioned in this show: Worry No More! book Download: Affirmations for Abundant Living LIAM Team Life Coaching Community Subscription/Social Links: Subscribe on iTunes! Subscribe on Stitcher Radio! Watch on YouTube! LIAM on Twitter: @LifeIs262 LIAM on Facebook / LifeIsAMarathon Subscribe to the LIAM Mailing List www.BruceVanHorn.com Bruce Van Horn on Twitter Bruce Van Horn on Facebook    

Angela Peabody is the founder and President of the Global Woman P.E.A.C.E. Foundation and has worked as a humanitarian for most of her adult life, supporting the Susan G. Komen Foundation, the Tigerlily Foundation and several other non-profit organizations. The Liberian Journalist and Novelist is an accomplished and award-winning writer. Her career has taken her to the corners of the earth, as she speaks out against female genital mutilation and other gender based violent acts. Global Woman P.E.A.C.E. Foundation is a 501c3 nonprofit organization. Funds raised from the upcoming 5K Walk will fund a Support System for FGM survivors, victims and would-be victims as well as educational and awareness programs. Angela is a highly sought after public speaker on issues of women empowerment and gender-based violence and has received many awards for her service to humanity. She is the former Chair of the Washington, D.C. Chapter of the National Writers Union, has served on the Board of Directors of the National Association of Women Business Owners and on the Advisory Board of Tigerlily Foundation. Visit the Foundation's website at www.globalwomanpeacefoundation.org Get the OFF TO WORK CD by Sister Jenna, like America Meditating on Facebook and follow us on Twitter.

When Oprah Winfrey tells you that you must write a book, you do it. Kathryn interviews breast cancer survivor Maimah Karmo, author of “Fearless: Awakening to my Life's Purpose Through Breast Cancer”. After her second chemotherapy treatment for breast cancer Maimah Karmo appeared on The Oprah Winfrey Show, where she was encouraged to document her journey from a 15 year old Liberian refugee to breast cancer survivor and advocate. Karmo is the founder of the Tigerlily Foundation, an organization that educates and empowers young women affected by breast cancer. Her work has been featured in Redbook Magazine and on Good Morning America.

When Oprah Winfrey tells you that you must write a book, you do it. Kathryn interviews breast cancer survivor Maimah Karmo, author of “Fearless: Awakening to my Life's Purpose Through Breast Cancer”. After her second chemotherapy treatment for breast cancer Maimah Karmo appeared on The Oprah Winfrey Show, where she was encouraged to document her journey from a 15 year old Liberian refugee to breast cancer survivor and advocate. Karmo is the founder of the Tigerlily Foundation, an organization that educates and empowers young women affected by breast cancer. Her work has been featured in Redbook Magazine and on Good Morning America.

Tune in as we talk with the Maimah Karmo founder of the Tigerlily Foundation. The Tigerlily Foundation is a organization geared to educate, empower, advocate for, support and inspire young women affected by breast cancer. Guest Bio - Maimah Karmo is a mother, daughter, sister, niece, cousin, friend and author. She is also a breast cancer survivor. On February 28, 2006, at 4:45 p.m., she was diagnosed with Stage 2breast cancer. She had no family history of breast cancer; and was only 32-years old. She had been doing all the right things – exercising, taking her vitamins and eating healthy. She didn’t fit the profile. She had been told by her doctor that she was too young to get breast cancer. How could this have happened? She didn't know the answer to that question, but she knew that her life would never be the same again. In May, after she had been given her second chemotherapy treatment, she decided to create an organization that would empower, educate, support and end isolation for young women affected by breast cancer. The organization was named Tigerlily Foundation (Tigerlily).